Program Pipeline

Our MAC-TAC technology platform is enabling the development of a broad portfolio of first-in-class pan-cancer therapeutics with the potential to overcome the limitations of existing treatments for solid tumors.

PROGRAMS

INDICATION

LEAD OPTIMIZATION

IND-ENABLING

PHASE 1

RS-5

Lead indications: soft tissue sarcomas (STS), melanoma
Broad applicability: pancreatic, prostate, gastric, renal, bladder

RS-8

Pan-cancer (solid tumors)

RS-7

Metastatic Disease

Linkedin-in

Copyright © 2024, Resolute Science, Inc. All Rights Reserved.